Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Mutations in the fms-like tyrosine kinase 3 ( FLT3 ) gene are detected in approximately one-third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the more common FLT3 -internal tandem duplication (ITD) in approximately 20–25% of AML cases, and point mutations in the t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-02-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/2040620719827310 |